SCHEMBL1750873

SCHEMBL1750873

CC(=O)N(C)C1CCN(c2ccc(NC(=O)N3CCC(c4ccc(Cl)cc4)CC3)c(F)c2)C1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 4/20 0.51
▸ FPR1 P21462 3/20 0.49
▸ FPR2 P25090 3/20 0.49
▸ MAPT P10636 3/20 0.45
▸ TP53 P04637 2/20 0.45
▸ HRH3 Q9Y5N1 2/20 0.44
▸ SETD2 Q9BYW2 2/20 0.44
▸ NSD2 O96028 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPC1 O15118 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ C5AR1 P21730 1/20 0.40
▸ F10 P00742 1/20 0.40
▸ CCR1 P32246 1/20 0.39
▸ USP30 Q70CQ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749494 0.90 MCHR1 (0.50) MCHR1FPR1FPR2MAPTTP53
SCHEMBL1749035 0.86 MCHR1 (0.64) MCHR1MAPTTP53HRH3SMN1; SMN2
SCHEMBL12528092 0.84 HRH3 (0.50) MCHR1FPR1FPR2MAPTTP53
SCHEMBL1748916 0.81 HRH3 (0.58) MCHR1MAPTHRH3SETD2NSD2
SCHEMBL1748965 0.81 MCHR1 (0.58) MCHR1MAPTTP53HRH3SMN1; SMN2
SCHEMBL1749654 0.80 MCHR1 (0.63) MCHR1MAPTTP53HRH3SMN1; SMN2
SCHEMBL1750699 0.80 HRH3 (0.61) MCHR1MAPTTP53HRH3SMN1; SMN2
SCHEMBL12528065 0.79 MCHR1 (0.59) MCHR1MAPTTP53HRH3SMN1; SMN2
SCHEMBL12528881 0.79 MCHR1 (0.75) MCHR1FPR1FPR2MAPTTP53
SCHEMBL1749301 0.78 HRH3 (0.58) MCHR1MAPTTP53HRH3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 — — US disclosed
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 — — US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 — — US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 — — US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 — — US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MCHR1 2068/4885FPR1 586/4885FPR2 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback